4D Molecular Therapeutics Stock Is Trading Higher Today - Here's Why
Portfolio Pulse from Vandana Singh
4D Molecular Therapeutics (NASDAQ:FDMT) announced positive interim data from the 4D-710 Phase 1/2 AEROW trial for cystic fibrosis lung disease. The aerosol delivery procedure was well tolerated, and biomarker analyses showed widespread CFTR expression. The company also recently released interim clinical data for wet age-related macular degeneration.
June 08, 2023 | 11:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
4D Molecular Therapeutics announced positive interim data from the 4D-710 Phase 1/2 AEROW trial for cystic fibrosis lung disease, leading to a 9.47% increase in stock price during premarket.
The positive interim data from the 4D-710 Phase 1/2 AEROW trial indicates that the aerosol delivery procedure is well tolerated and shows promising results for cystic fibrosis lung disease treatment. This news is directly related to FDMT's product pipeline and has led to a 9.47% increase in stock price during premarket, indicating a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100